X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (82) 82
trametinib (80) 80
humans (61) 61
oncology (61) 61
melanoma (51) 51
mutation (35) 35
cancer (32) 32
mek inhibitor (32) 32
tumors (32) 32
kinases (27) 27
female (26) 26
male (25) 25
braf (23) 23
pharmacology & pharmacy (23) 23
protein kinase inhibitors - therapeutic use (23) 23
animals (22) 22
middle aged (22) 22
pyridones - therapeutic use (21) 21
pyrimidinones - therapeutic use (21) 21
antineoplastic agents - therapeutic use (20) 20
aged (19) 19
melanoma - drug therapy (19) 19
open-label (19) 19
metastasis (18) 18
adult (17) 17
care and treatment (17) 17
combination (17) 17
map kinase kinase 1 - antagonists & inhibitors (17) 17
dabrafenib (16) 16
genetic aspects (16) 16
protein kinase inhibitors - pharmacology (16) 16
research (16) 16
cancer therapies (15) 15
metastatic melanoma (15) 15
mutations (15) 15
improved survival (14) 14
map kinase (14) 14
health aspects (13) 13
mek inhibitors (13) 13
pancreatic cancer (13) 13
proteins (13) 13
pyridones - administration & dosage (13) 13
pyrimidinones - administration & dosage (13) 13
vemurafenib (13) 13
antineoplastic combined chemotherapy protocols - therapeutic use (12) 12
clinical trials (12) 12
drug therapy (12) 12
gene mutations (12) 12
medicine & public health (12) 12
mek (12) 12
neoplasms (12) 12
nras (12) 12
pathway (12) 12
pyridones - pharmacology (12) 12
pyrimidinones - pharmacology (12) 12
cell line, tumor (11) 11
development and progression (11) 11
inhibitors (11) 11
kras (11) 11
map kinase kinase 2 - antagonists & inhibitors (11) 11
medical prognosis (11) 11
mice (11) 11
mitogen-activated protein kinase kinases - antagonists & inhibitors (11) 11
mitogens (11) 11
neoplasms - drug therapy (11) 11
neoplasms. tumors. oncology. including cancer and carcinogens (11) 11
oral mek inhibitor (11) 11
phase-ii (11) 11
phosphorylation (11) 11
pyridones - adverse effects (11) 11
pyrimidinones - adverse effects (11) 11
treatment outcome (11) 11
apoptosis (10) 10
cell growth (10) 10
chemotherapy (10) 10
colorectal cancer (10) 10
dose-escalation trial (10) 10
lung cancer (10) 10
mek inhibition (10) 10
patients (10) 10
review (10) 10
signal transduction - drug effects (10) 10
skin neoplasms - drug therapy (10) 10
trametinib gsk1120212 (10) 10
advanced solid tumors (9) 9
antineoplastic agents - adverse effects (9) 9
antineoplastic agents - pharmacology (9) 9
cell biology (9) 9
gsk1120212 (9) 9
melanoma - pathology (9) 9
molecular targeted therapy (9) 9
protein kinase inhibitors - adverse effects (9) 9
proto-oncogene proteins p21 - genetics (9) 9
signal transduction (9) 9
survival (9) 9
acquired-resistance (8) 8
activation (8) 8
adenocarcinoma (8) 8
aged, 80 and over (8) 8
antimitotic agents (8) 8
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Recent Results in Cancer Research, ISSN 0080-0015, 2018, Volume 211, pp. 91 - 100
Journal Article
Annals of Oncology, ISSN 0923-7534, 2015, Volume 26, Issue 5, pp. 894 - 901
Background: KRAS mutations are detected in 25% of non-small-cell lung cancer (NSCLC) and no targeted therapies are approved for this subset population.... 
KRAS | MEK inhibitor | NSCLC | Progression-free survival | Trametinib | Docetaxel | SURVIVAL | CRITERIA | EFFICACY | progression-free survival | BEHAVIOR | ADENOCARCINOMAS | trametinib | TYROSINE KINASE INHIBITORS | GROWTH-FACTOR RECEPTOR | ONCOGENE | MEK INHIBITION | ONCOLOGY | docetaxel | MUTATIONS | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Proto-Oncogene Proteins p21(ras) - genetics | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Protein Kinase Inhibitors - adverse effects | Taxoids - therapeutic use | Time Factors | Adult | Female | Antineoplastic Agents, Phytogenic - therapeutic use | Taxoids - adverse effects | Antineoplastic Agents, Phytogenic - adverse effects | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | MAP Kinase Kinase 1 - antagonists & inhibitors | Lung Neoplasms - enzymology | Carcinoma, Non-Small-Cell Lung - genetics | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Kaplan-Meier Estimate | MAP Kinase Kinase 1 - metabolism | Treatment Outcome | MAP Kinase Kinase 2 - metabolism | Carcinoma, Non-Small-Cell Lung - mortality | Disease Progression | Disease-Free Survival | Signal Transduction - drug effects | MAP Kinase Kinase 2 - antagonists & inhibitors | Protein Kinase Inhibitors - therapeutic use | Aged | Biomarkers, Tumor - genetics | Pyridones - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Pyridones - adverse effects | Original
Journal Article
Annals of Oncology, ISSN 0923-7534, 01/2015, Volume 26, Issue 1, pp. 58 - 64
Journal Article
Journal Article
Investigational New Drugs, ISSN 0167-6997, 10/2015, Volume 33, Issue 5, pp. 1058 - 1067
Journal Article
CANCER RESEARCH, ISSN 0008-5472, 11/2019, Volume 79, Issue 21, pp. 5612 - 5625
Mutated KRAS protein is a pivotal tumor driver in pancreatic cancer. However, despite comprehensive efforts, effective therapeutics that can target oncogenic... 
PATHWAYS | TUMOR XENOGRAFTS | ONCOLOGY | ONCOGENIC KRAS | ORAL MEK INHIBITOR | MUTANT CANCERS | SENESCENCE | REGULATORS | COMBINATION | TRAMETINIB GSK1120212 | GEMCITABINE
Journal Article
Cold Spring Harbor Perspectives in Medicine, ISSN 2157-1422, 09/2018, Volume 8, Issue 9
RAS genes (HRAS, KRAS, and NRAS) comprise the most frequently mutated oncogene family in human cancer. With the highest RAS mutation frequencies seen with the... 
RNA INTERFERENCE | PLUS GEMCITABINE | MEDICINE, RESEARCH & EXPERIMENTAL | ADVANCED SOLID TUMORS | K-RAS | DUCTAL ADENOCARCINOMA | ONCOGENIC KRAS | ORAL MEK INHIBITOR | RAF INHIBITORS | INTRAEPITHELIAL NEOPLASIA | TRAMETINIB GSK1120212
Journal Article
Lung Cancer, ISSN 0169-5002, 07/2019, Volume 133, pp. 88 - 95
MCL1 is an anti-apoptotic BCL2 family member that is highly expressed in various malignant tumors. However, little is known about the role of MCL1 in -mutant... 
KRAS-mutant lung adenocarcinoma | Bcl-xL | Trametinib | MCL1 | Apoptosis | EPITHELIAL-MESENCHYMAL TRANSITION | SURVIVAL | ONCOLOGY | RESPIRATORY SYSTEM | GSK1120212 | LINES | Adenocarcinoma | Respiratory agents | Health aspects | Lung cancer
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 07/2019, Volume 154, Issue 1, pp. 95 - 101
Improved treatment for advanced cervical cancer is needed; currently, treatment options include combined chemotherapy and bevacizumab or pembrolizumab... 
MEK inhibitor | AKT inhibitor | Targeted therapy | Trametinib | Cervical cancer | MEK INHIBITOR TRAMETINIB | MUTANT | AKT | COMBINATION | ANT inhibitor | TUMORS | OBSTETRICS & GYNECOLOGY | PATHWAY ACTIVATION | PI3K | ONCOLOGY | GSK1120212 | Relapse | Clinical trials | Diarrhea | Nausea | Health aspects | Diseases
Journal Article
Journal Article
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, ISSN 0027-8424, 03/2019, Volume 116, Issue 10, pp. 4508 - 4517
Journal Article
Scientific Reports, ISSN 2045-2322, 06/2016, Volume 6, Issue 1, p. 28260
Although the translational function of tRNA has long been established, extra translational functions of tRNA are still being discovered. We previously... 
DOSE-ESCALATION | ADVANCED SOLID TUMORS | PROTEIN | DUCTAL ADENOCARCINOMA | INHIBITOR TRAMETINIB | MEK1/2 INHIBITOR | MULTIDISCIPLINARY SCIENCES | IN-VIVO | COMBINATION | TRAMETINIB GSK1120212 | GEMCITABINE
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2013, Volume 49, Issue 9, pp. 2077 - 2085
Journal Article
Cell Cycle, ISSN 1538-4101, 12/2015, Volume 14, Issue 23, pp. 3713 - 3724
Purpose: Over 90% of pancreatic adenocarcinoma PC express oncogenic mutant KRAS that constitutively activates the Raf-MEK-MAPK pathway conferring resistance to... 
trametinib |